Table 2.
Anti-SMV HBGA blockade antibody response to SMV challenge in pre- and post- samples
| Infection Statusa | |||
|---|---|---|---|
| Infected (n = 25) | Uninfected (n = 8) | P valuec | |
| Day 1b | |||
| N | 25 | 8 | |
| GMT (95% CI) | 20.6 (16.0, 26.6) | 25.0 (17.2, 36.4) | 0.257 |
| GMFR (95% CI) | 0 | 0 | |
| Day 6 | |||
| N | 23 | 6 | |
| GMT (95% CI) | 31.8 (21.1, 48.0) | 50.0 (21.9, 114.4) | 0.201 |
| GMFR (95% CI) | 1.6 (1.2, 2.0) | 1.6 (0.9, 3.0) | 0.935 |
| Day 15 | |||
| N | 23 | 6 | |
| GMT (95% CI) | 295.9 (141.4, 619.5) | 67.3 (22.4, 202.5) | 0.031 |
| GMFR (95% CI) | 14.6 (7.0, 30.7) | 2.21 (0.9, 5.6) | 0.018 |
| Day 30 | |||
| N | 23 | 5 | |
| GMT (95% CI) | 247.0 (121.6, 501.5) | 50.0 (13.6, 183.7) | 0.034 |
| GMFR (95% CI) | 12.2 (6.0, 25.0) | 1.6 (0.5, 5.2) | 0.011 |
| Day 45 | |||
| N | 22 | 5 | |
| GMT (95% CI) | 171.0 (93.8, 311.1) | 50.0 (17.9, 139.9) | 0.037 |
| GMFR (95% CI) | 8.5 (4.7, 15.6) | 1.59 (0.7, 3.8) | 0.010 |
a
Infection was defined as SMV RNA positive in any post-challenge stool sample detected by RT-qPCR.
b
Day 1 was pre-challenge
c
Kruskal-Wallis P value indicating probability of statistically significant difference in GMT and GMFR between infected and uninfected subjects post challenge
Abbreviation: CI - confidence interval, GMT - geometric mean antibody titers, GMFR - geometric mean fold rise